Rozlytrek — Medical Mutual
Non-Small Cell Lung Cancer (ROS1-positive metastatic disease)
Initial criteria
- Patient is an adult
- Disease is ROS1-positive
- Disease is metastatic
Reauthorization criteria
- Patient has not experienced intolerable side effects
- Patient has had a beneficial response to therapy, per the prescribing physician
Approval duration
1 year